argenx SE Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-09-2023 09:00 AM Transcript
Great. Good morning. I'm James Gordon, JPMorgan European pharma and biotech analyst. And today, I've got the pleasure of introducing the argenx presentation. And you're going to hear from argenx CEO, Tim Van Hauwermeiren. And then we're going to have the Q&A in this room as well. So 20 minutes of presentation and then 20 minutes of Q&A. And if you've got any questions, you can also register those questions, and I can read them off the iPad or you'll be able to put your hand up, and we'll do live questions. So with that said, thanks a lot for joining us today, Tim.
Thank you, James. And a very warm welcome to all of you, ladies and gentlemen. It's exactly 1 year ago since we launched VYVGART here in the United States. And since that day, very powerful patient anecdotes are reaching us at argenx. And I thought I would start today by sharing 2 very recent stories of our VYVGART patients.
The first
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
